<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39432643</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>42</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Advances in research on medications for the treatment of alcohol use disorders: A review.</ArticleTitle><Pagination><StartPage>e40045</StartPage><MedlinePgn>e40045</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e40045</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000040045</ELocationID><Abstract><AbstractText>Alcohol use disorder (AUD) has become a global public health challenge, with the social and economic costs of alcohol abuse escalating, drawing widespread attention from healthcare professionals and the public worldwide. Particularly in recent years, the COVID-19 pandemic and associated lockdown measures have led to a significant increase in global alcohol consumption, further exacerbating the risk of AUD and sparking in-depth discussions on its prevention and treatment methods. Given that the current mainstay of AUD treatment relies on pharmacotherapy, the aim of this article is to review the progress of existing drug research for the treatment of AUD, and at the same time to focus on drug classes that have not yet been applied to the clinic, but have been shown in recent studies to be potentially exploitable for the treatment of AUD, in order to provide new ideas and directions for future drug research and development efforts.</AbstractText><CopyrightInformation>Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yuzhou</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0007-7692-3628</Identifier><AffiliationInfo><Affiliation>Jining Medical University, Jining, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zong</LastName><ForeName>Luxin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Shandong Daizhuang Hospital, Jining, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Qunde</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Jining Medical University, Jining, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chuanxin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0002-3438-0702</Identifier><AffiliationInfo><Affiliation>Jining Medical University, Jining, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000427">Alcohol Deterrents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="Y">Alcoholism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000427" MajorTopicYN="N">Alcohol Deterrents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no funding and conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>22</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>14</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39432643</ArticleId><ArticleId IdType="pmc">PMC11495768</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000040045</ArticleId><ArticleId IdType="pii">00005792-202410180-00059</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ferraguti G, Pascale E, Lucarelli M. Alcohol addiction: a molecular biology perspective. Curr Med Chem. 2015;22:670–84.</Citation><ArticleIdList><ArticleId IdType="pubmed">25544474</ArticleId></ArticleIdList></Reference><Reference><Citation>Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. Sci Adv. 2019;5:eaax4043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6760932</ArticleId><ArticleId IdType="pubmed">31579824</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet (London, England). 2009;373:2223–33.</Citation><ArticleIdList><ArticleId IdType="pubmed">19560604</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaziano L, Giambartolomei C, Pereira AC, et al. . Actionable druggable genome-wide mendelian randomization identifies repurposing opportunities for covid-19. Nat Med. 2021;27:668–76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7612986</ArticleId><ArticleId IdType="pubmed">33837377</ArticleId></ArticleIdList></Reference><Reference><Citation>White AM, Castle I-JP, Powell PA, et al. . Alcohol-related deaths during the covid-19 pandemic. JAMA. 2022;327:1704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8933830</ArticleId><ArticleId IdType="pubmed">35302593</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnette EM, Nieto SJ, Grodin EN, et al. . Novel agents for the pharmacological treatment of alcohol use disorder. Drugs. 2022;82:251–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8888464</ArticleId><ArticleId IdType="pubmed">35133639</ArticleId></ArticleIdList></Reference><Reference><Citation>Castrén S, Mäkelä N, Alho H. Selecting an appropriate alcohol pharmacotherapy: review of recent findings. Curr Opin Psychiatry. 2019;32:266–74.</Citation><ArticleIdList><ArticleId IdType="pubmed">30973369</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol. 2014;77:315–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4014018</ArticleId><ArticleId IdType="pubmed">23278595</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohoff FW. Pharmacotherapies and personalized medicine for alcohol use disorder: a review. Pharmacogenomics. 2020;21:1117–38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7586357</ArticleId><ArticleId IdType="pubmed">32807012</ArticleId></ArticleIdList></Reference><Reference><Citation>Rösner S, Hackl-Herrwerth A, Leucht S, et al. . Acamprosate for alcohol dependence[J/OL]. Cochrane Database of Systematic Reviews, 2010. [2023–12–07].</Citation><ArticleIdList><ArticleId IdType="pubmed">20824837</ArticleId></ArticleIdList></Reference><Reference><Citation>Caputo F, Vignoli T, Grignaschi A, Cibin M, Addolorato G, Bernardi M. Pharmacological management of alcohol dependence: from mono-therapy to pharmacogenetics and beyond. Eur Neuropsychopharmacol. 2014;24:181–91.</Citation><ArticleIdList><ArticleId IdType="pubmed">24182622</ArticleId></ArticleIdList></Reference><Reference><Citation>Swift RM. Drug therapy for alcohol dependence. N Engl J Med. 1999;340:1482–90.</Citation><ArticleIdList><ArticleId IdType="pubmed">10320388</ArticleId></ArticleIdList></Reference><Reference><Citation>Skinner MD, Lahmek P, Pham H, Aubin H-J. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014;9:e87366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3919718</ArticleId><ArticleId IdType="pubmed">24520330</ArticleId></ArticleIdList></Reference><Reference><Citation>Anton RF, Schacht JP, Book SW. Pharmacologic treatment of alcoholism. Handb Clin Neurol. 2014;125:527–42.</Citation><ArticleIdList><ArticleId IdType="pubmed">25307594</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbaizar B, Diersen-Sotos T, Gómez-Acebo I, Llorca J. Topiramate in the treatment of alcohol dependence: a meta-analysis. Actas Esp Psiquiatr. 2010;38:8–12.</Citation><ArticleIdList><ArticleId IdType="pubmed">20931405</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry. 2010;71:634–48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3736141</ArticleId><ArticleId IdType="pubmed">20361908</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BA, Ait-Daoud N, Bowden CL, et al. . Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet (London, England). 2003;361:1677–85.</Citation><ArticleIdList><ArticleId IdType="pubmed">12767733</ArticleId></ArticleIdList></Reference><Reference><Citation>De Beaurepaire R. A review of the potential mechanisms of action of baclofen in alcohol use disorder. Front Psychiatry. 2018;9:506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6232933</ArticleId><ArticleId IdType="pubmed">30459646</ArticleId></ArticleIdList></Reference><Reference><Citation>Rollema H, Chambers LK, Coe JW, et al. . Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology. 2007;52:985–94.</Citation><ArticleIdList><ArticleId IdType="pubmed">17157884</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer P, Fehr C. Efficacy of varenicline in patients with severe alcohol dependence: a pilot double-blind randomized and controlled study. J Clin Psychopharmacol. 2019;39:398–402.</Citation><ArticleIdList><ArticleId IdType="pubmed">31188242</ArticleId></ArticleIdList></Reference><Reference><Citation>Litten RZ, Ryan ML, Fertig JB, et al. . A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med. 2013;7:277–86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3914416</ArticleId><ArticleId IdType="pubmed">23728065</ArticleId></ArticleIdList></Reference><Reference><Citation>Kranzler HR, Feinn R, Morris P, Hartwell EE. A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Addiction. 2019;114:1547–55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6682454</ArticleId><ArticleId IdType="pubmed">31077485</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zhu Y. Different doses of gabapentin formulations for postherpetic neuralgia: a systematical review and meta-analysis of randomized controlled trials. J Dermatolog Treat. 2017;28:65–77.</Citation><ArticleIdList><ArticleId IdType="pubmed">27798973</ArticleId></ArticleIdList></Reference><Reference><Citation>Leggio L, Hendershot CS, Farokhnia M, et al. . GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nat Med. 2023;29:2993–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">38001271</ArticleId></ArticleIdList></Reference><Reference><Citation>Quddos F, Hubshman Z, Tegge A, et al. . Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep. 2023;13:20998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10684505</ArticleId><ArticleId IdType="pubmed">38017205</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield SF, Weiss RD, Muenz LR, et al. . The effect of depression on return to drinking: a prospective study. Arch Gen Psychiatry. 1998;55:259–65.</Citation><ArticleIdList><ArticleId IdType="pubmed">9510220</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers RA. Adult hippocampal neurogenesis in the pathogenesis of addiction and dual diagnosis disorders. Drug Alcohol Depend. 2013;130:1–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640791</ArticleId><ArticleId IdType="pubmed">23279925</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates ME, Buckman JF, Nguyen TT. A role for cognitive rehabilitation in increasing the effectiveness of treatment for alcohol use disorders. Neuropsychol Rev. 2013;23:27–47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3610413</ArticleId><ArticleId IdType="pubmed">23412885</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabski M, McAndrew A, Lawn W, et al. . Adjunctive ketamine with relapse prevention–based psychological therapy in the treatment of alcohol use disorder. Am J Psychiatry. 2022;179:152–62.</Citation><ArticleIdList><ArticleId IdType="pubmed">35012326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivan Ezquerra-Romano I, Lawn W, Krupitsky E, Morgan CJA. Ketamine for the treatment of addiction: evidence and potential mechanisms. Neuropharmacology. 2018;142:72–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">29339294</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen R-T, Zhang F-F, Zhang H-T. Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorder. Psychopharmacology (Berl). 2018;235:1793–805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5949271</ArticleId><ArticleId IdType="pubmed">29663017</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng L, Aimaiti Z, Long L, Xia C, Wang W, Zhou Z-Z. Discovery of 4-ethoxy-6-chloro-5-azaindazoles as novel pde4 inhibitors for the treatment of alcohol use disorder and alcoholic liver diseases. J Med Chem. 2024;67:728–53.</Citation><ArticleIdList><ArticleId IdType="pubmed">38156615</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>